

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

April 17, 2024

Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. 590 Madison Ave., 21st Floor New York, NY 10022

Re: Hoth Therapeutics, Inc.
Registration Statement on Form S-1
Filed April 11, 2024
File No. 333-278620

Dear Robb Knie:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Emily A. Mastoloni, Esq.